The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. | ITV National News ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

Blood cancer patients in England will be the first in the world to be offered a 'Trojan horse' drug. Thousands of patients ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

The global IPV vaccines market is estimated to be valued at USD 199.9 Mn in 2025 and expected to reach at USD 358.5 Mn by 2032 With a CAGR of 8.7% during the forecast period (2025-2032). Coherent ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International.

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...